{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-005981","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2024-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.564459+00:00","generated_at":"2026-06-02T03:53:29.729172+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ENDRA Life Sciences reports expected Q1 2024 net loss of ~$2.8M, zero revenue; files for public offering","bullets":["Expected Q1 2024 net loss of approx. $2.8M vs. $2.9M in Q1 2023; zero revenue in both quarters.","As of March 31, 2024, total assets ~$5.0M, cash ~$1.1M, working capital only ~$54k.","Filed Form S-1/A for public offering of common stock and warrants; terms not disclosed.","Preliminary results are unaudited and subject to final closing and audit adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-005981","json":"https://secwatch.observer/filing/0001654954-24-005981.json","markdown":"https://secwatch.observer/filing/0001654954-24-005981.md","text":"https://secwatch.observer/filing/0001654954-24-005981.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424005981/0001654954-24-005981-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424005981/ndra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T03:53:29.729172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"83c180f2c39fcd86e636efe265d08649005e9539","claim":"ENDRA Life Sciences Inc. reported the fiscal quarter ended March 31, 2024 results: net income We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2024.","evidence_excerpt":"On May 10, 2024, ENDRA Life Sciences Inc. (the “Company”) filed a Registration Statement (the “Prospectus”) on Form S-1/A (No. 333-278842) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), relating to a public offering (the “Offering”) of shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock. The Prospectus contains select preliminary unaudited estimated financial results for the fiscal quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424005981/0001654954-24-005981-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended March 31, 2024"},{"label":"Net income","value":"We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2024"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}